HLA-A24-restricted cancer antigen peptides

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,420,034
App. No.: 10/517,600
Granted: Sep 2, 2008
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

HLA-A24-restricted peptides derived from WT1 which have an activity to induce CTLs in vivo, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. The cancer vaccines of the present invention may be used to treat many cancer patients.

Claims (6)

1. A isolated peptide which comprises the amino acid sequence of:

(SEQ ID NO: 2)

Arg Tyr Phe Pro Asn Ala Pro Tyr Leu.

2. The isolated peptide according to claim 1 , which consists of the amino acid sequence of SEQ ID NO: 2.

3. A pharmaceutical composition which comprises the peptide according to claim 1 or claim 2 , together with a pharmaceutically acceptable carrier.

4. An isolated peptide of SEQ ID NO: 2.

Assignments (6)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2017

From: SUMITOMO DAINIPPON PHARMA CO., LTD.

To: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.

Reel/Frame 043305/0542 →